Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on Libtayo (cemiplimab) - Direct communication with healthcare professionals on Libtayo (cemiplimab)
Direct communication with healthcare professionals on Libtayo (cemiplimab)
Libtayo (cemiplimab) 350 mg concentrate for solution for infusion: Batch / lot number and expiry date may become illegible following sanitisation and wiping of vial label.
Summary:
- The batch / lot number and expiry date on the Libtayo® 350 mg vial label may become illegible upon sanitisation / disinfection followed by physical wiping of the vial during the initial preparation of the infusion.
- The Libtayo batch / lot number and expiry date should be recorded from the vial label before sanitisation / disinfection.
- Neither product efficacy nor patient safety is impacted by this issue.
Published on: 10 November 2025
#AIFA promuove l’ascolto e la trasparenza
Approvati i Regolamenti di “AIFA Ascolta” e “AIFA Incontr...
Vai al post →
Oggi si celebra il #WorldAutismAwarenessDay.
🔵 L'Agenzia Italiana del Farmaco sostiene la Giornata...
Vai al post →
Jelena Ivanovic, dirigente medico dell’Ufficio Procedure Europee di #HTA di #AIFA, è stata eletta Co...
Vai al post →
Biosimilari: webinar AIFA su terzo Position Paper
La Commissione Scientifica ed Economica (CSE) di ...
Vai al post →
🎙️ Il Presidente #AIFA intervistato da @presadirettarai sulle false terapie a base di cellule stami...
Vai al post →
💛 28 marzo 2026 – Giornata Mondiale dell’Endometriosi 💛
#AIFA si illumina di giallo per accendere...
Vai al post →
